Cannabidiol/Tetrahydrocannabivarin(Cannabidiol/Tetrahydrocannabivarin) - 药物靶点：CB1R x CB2_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Cannabidiol/delta-9-tetrahydrocannabivarin、Cannabidiol/tetrahydrocannabivarin-9、THCV/CBD

+ [3]

靶点

CB1R x CB2

作用方式

拮抗剂

作用机制

CB1拮抗剂(大麻素受体CB1拮抗剂)、CB2拮抗剂(大麻素受体CB2拮抗剂)

治疗领域

内分泌与代谢疾病

在研适应症-

非在研适应症

2型糖尿病血脂障碍代谢综合征+ [1]

原研机构

GW Pharmaceuticals Ltd.

在研机构-

非在研机构

GW Pharmaceuticals Ltd.

University of Buckingham

Jazz Pharmaceuticals Plc

权益机构-

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C19H26O2

InChIKeyZROLHBHDLIHEMS-HUUCEWRRSA-N

CAS号31262-37-0

查看全部结构式(2)

关联

7

项与 Cannabidiol/Tetrahydrocannabivarin 相关的临床试验

NCT03550352

/ Terminated临床2期IIT

Cannabinoids in People Living With HIV on Effective Antiretroviral Therapy: A Pilot Study to Assess Safety, Tolerability and Effect on Immune Activation

The purpose of this pilot study is to assess feasibility and to examine whether oral cannabinoids (capsules containing either Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) combined or CBD alone) are safe and well-tolerated in people living with HIV. Other aims are to determine whether oral cannabinoids may reduce HIV-associated inflammation. An exploratory objective is to determine whether oral cannabinoids may influence HIV persistence as well as the gastrointestinal microbiome.

开始日期2021-08-20

申办/合作机构

Centre universitaire de santé McGill

[+3]

NCT04992962

/ Unknown status临床2期

A Double-Blind, Randomized, Placebo-Controlled, Three-Arm Trial Examining Sublingual Cannabinoid Tablets for the Treatment of Pain From Osteoarthritis of the Knee.

The purpose of the study is to evaluate the efficacy of PG-OA-10CN and PG-OA-5TH tablets as a better pain reliever in patients with moderate to severe chronic pain due to osteoarthritis of the knee than a placebo.

开始日期2021-07-29

申办/合作机构

PURE-GREEN YK

NCT04851392

/ CompletedN/AIIT

Do Adolescents and Adults Differ in Their Acute Subjective, Behavioural and Neural Responses to Cannabis, With and Without Cannabidiol?

The acute effects of cannabis may differ between adolescents and adults. Furthermore, these effects may be tempered by the presence of cannabidiol. This double-blind, placebo-controlled, crossover experiment investigates the acute effects of cannabis (with and without cannabidiol) on subjective effects, behavioural responses and neural functioning in 16-17 year-olds and 26-29 year-olds who regularly use cannabis (0.5-3 days per week).

开始日期2019-03-11

申办/合作机构

University College London

[+2]

100 项与 Cannabidiol/Tetrahydrocannabivarin 相关的临床结果

登录后查看更多信息

100 项与 Cannabidiol/Tetrahydrocannabivarin 相关的转化医学

登录后查看更多信息

100 项与 Cannabidiol/Tetrahydrocannabivarin 相关的专利（医药）

登录后查看更多信息

100 项与 Cannabidiol/Tetrahydrocannabivarin 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床2期	英国	GW Pharmaceuticals Ltd.	-
2型糖尿病	临床2期	-	University of Buckingham	-
血脂障碍	临床2期	-	University of Buckingham	-
代谢综合征	临床2期	-	University of Buckingham	-
代谢综合征	临床2期	英国	GW Pharmaceuticals Ltd.	-
肥胖	临床2期	英国	GW Pharmaceuticals Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01491490 (GWMD09126, CTgov)	临床2期	血脂障碍	2	GWP42003 : GWP42004 (40:1) (GWP42003 : GWP42004 (40:1))	憲簾鹹築齋顧積選壓憲(願鬱艱繭構廠襯齋廠鏇) = 範鬱憲選繭顧構齋獵觸範簾選鹽鹹衊蓋鏇築網 (醖製齋範襯築齋襯積觸, 選餘膚壓構繭餘餘餘顧 ~ 蓋壓觸選憲顧鏇鹽鹹範) 更多	-	2013-11-01
				Placebo (Placebo)	憲簾鹹築齋顧積選壓憲(願鬱艱繭構廠襯齋廠鏇) = 築範鑰衊繭繭鏇憲齋繭範簾選鹽鹹衊蓋鏇築網 (醖製齋範襯築齋襯積觸, 糧觸衊襯簾鏇醖顧糧鏇 ~ 淵艱膚鹽構觸醖餘淵廠) 更多